Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
Therapeutic efficacy and oncological prognosis of ypTNM 0-I gastric cancer after neoadjuvant therapy: a multicenter propensity-score matched study in China.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cui Hao, Lu Yuyuan, Ren Huiguang, Song Liqiang, Yuan Zhen, Liu Yuchen, Li Rui, Chen Lin, Lu Canrong, Cui Jianxin, Wei Bo
Аннотация
BACKGROUND: Neoadjuvant therapy (NAT) effectively downstages locally advanced gastric cancer (LAGC), increasing the proportion of patients achieving ypTNM stage 0-I. However, it is still controversial whether the LAGC patients with better tumor regression (ypTNM stage 0-I) had similar prognosis compared with pTNM I early gastric cancer (EGC) patients or not. This study compared short- and long-term outcomes between ypTNM 0-I LAGC and EGC patients.
METHODS: A retrospective analysis of 1,193 patients with pTNM I EGC or ypTNM 0-I LAGC treated between January 2020 and November 2024 from three medical centers was conducted. Propensity score matching (PSM) at a 1:1 ratio balanced baseline characteristic. Short- and long-term outcomes were compared between groups.
RESULTS: After PSM, baseline characteristics were comparable with no significant difference (P > 0.05). The ypTNM 0-I group had longer operative times, greater estimated blood loss, and extended postoperative hospital days compared with pTNM I group (P < 0.05), but no differences in complication rates, recurrence rates, 3-year overall survival (OS: 93.3% vs. 90.1%, P = 0.608) and recurrence-free survival (RFS: 90.3% vs. 87.7%, P = 0.301) between two groups. Multivariable Cox analysis identified nerve invasion as an independent risk factor for OS and RFS, while preoperative CEA ≥ 2.5 ng/mL was associated with poorer RFS (P < 0.05).
CONCLUSION: LAGC patients achieving ypTNM 0-I after NAT had comparable short- and long-term outcomes to pTNM I EGC patients. Nerve invasion and CEA levels ≥ 2.5 ng/mL were prognostic indicators for poorer survival.
METHODS: A retrospective analysis of 1,193 patients with pTNM I EGC or ypTNM 0-I LAGC treated between January 2020 and November 2024 from three medical centers was conducted. Propensity score matching (PSM) at a 1:1 ratio balanced baseline characteristic. Short- and long-term outcomes were compared between groups.
RESULTS: After PSM, baseline characteristics were comparable with no significant difference (P > 0.05). The ypTNM 0-I group had longer operative times, greater estimated blood loss, and extended postoperative hospital days compared with pTNM I group (P < 0.05), but no differences in complication rates, recurrence rates, 3-year overall survival (OS: 93.3% vs. 90.1%, P = 0.608) and recurrence-free survival (RFS: 90.3% vs. 87.7%, P = 0.301) between two groups. Multivariable Cox analysis identified nerve invasion as an independent risk factor for OS and RFS, while preoperative CEA ≥ 2.5 ng/mL was associated with poorer RFS (P < 0.05).
CONCLUSION: LAGC patients achieving ypTNM 0-I after NAT had comparable short- and long-term outcomes to pTNM I EGC patients. Nerve invasion and CEA levels ≥ 2.5 ng/mL were prognostic indicators for poorer survival.